Leading Product Candidates
Spero Therapeutics is developing a portfolio of novel product candidates with the potential for meaningful patient impact and significant commercial applications. Our candidates are designed to treat MDR bacterial infections in both the hospital and community settings.
Talented Team of People with a Mission to Save Lives
Spero has been named one of the 2020 Best Places to Work by the Boston Business Journal.
-
Tebipenem HBr
Oral Candidate to Treat MDR Gram-Negative Infections
Novel antibiotic currently in a Phase 3 pivotal trial with the potential to be the first oral carbapenem for use in adults in treating cUTI.
-
SPR720
Oral Candidate to Treat Non-tuberculous Mycobacterial Disease
Novel agent with the potential to be the first oral antibiotic approved for the treatment of NTM disease.
- Spero Therapeutics to Present at Investor Conferences in September
- Spero Therapeutics Announces Pricing of Securities Offering
- Spero Therapeutics Announces Proposed Public Offering
- Spero Therapeutics Announces Positive Topline Results from its Phase 3 ADAPT-PO Clinical Trial of Oral Tebipenem HBr in Complicated Urinary Tract Infection and Acute Pyelonephritis
-
Investors
Learn about the investment opportunity, see our upcoming events and download our latest corporate presentation.
Investment opportunities > -
Careers
Join a passionate team that pushes the limits in finding innovative therapies to help patients.
Career opportunities > -
Partners
Our strategic partnerships foster mutually beneficial alliances that advance medicine to improve patient lives.
Partnership opportunities >
